v1
Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer.
Identifier:nobleid.org/w1/20260515/6C7B32FD
Type:Journal Article
0 views
Embeddable Badge
[](https://nobleid.org/work/w1/20260515/6C7B32FD)
Bibliometric Analysis
Impact metrics, research fronts, co-authorship networks →
Authors & Claims